Relapse-free survival

Median RFS was 15.5 months in patients who achieved CR/CRi (n=35)2

Relapse-free survival rate graph Relapse-free survival rate graph

Pinch to zoom

  • RFS and OS were secondary endpoints of the ZUMA-3 phase 2, single-arm, open-label study4
  • RFS and OS data are descriptive and should be carefully interpreted in light of the single-arm study design

71% estimated 1-year OS rate (95% CI: 56, 81)2

  • Median 18.2 months OS in all efficacy-evaluable patients treated with TECARTUS (n=54)
  • In patients who achieved CR/CRi (n=35), median OS was not reached at 15.5 months OS follow-up

6-month RFS rates were consistent across subgroups,
including primary refractory patients and patients with Ph+ disease,
prior allo-SCT, or prior blinatumomab2

ALL=acute lymphoblastic leukemia; allo-SCT=allogeneic stem cell transplant; Cl=confidence interval; CR=complete remission; CRi=complete remission with incomplete hematologic recovery; Ph+=Philadelphia chromosome positive; RFS=relapse-free survival; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502. 3. Data on file. Kite Pharma, Inc; 2021.